BTIG analyst Thomas Shrader maintained a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) Inc on Thursday, setting a price target of $91, which is approximately 95.83% above the present share price of $46.47.
Shrader expects BridgeBio Pharma Inc to post earnings per share (EPS) of -$1.01 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in BridgeBio Pharma, with an average price target of $81.75.
The analysts price targets range from a high of $91 to a low of $71.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $122 thousand and a net profit of -$127.49 million. The company's market cap is $6.94 billion.
According to TipRanks.com, BTIG analyst Thomas Shrader is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.6% and a 39.71% success rate.
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick (NYSE:MKC), Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.